Leucine-rich repeat kinase 2 modulates neuroinflammation and neurotoxicity in models of human immunodeficiency virus 1-associated neurocognitive disorders

Journal of Neuroscience

Volumn 35, Issue 13, 2015, Pages 5271-5283

  Puccini, Jenna M ^a   Marker, Daniel F ^a   Fitzgerald, Tim ^c   Barbieri, Justin ^a   Kim, Christopher S ^a   Miller Rhodes, Patrick ^a   Lu, Shao Ming ^a   Dewhurst, Stephen ^b   Gelbard, Harris A ^a  

^a Center for Neural Development and Disease   (United States)

^b UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^c ROCHESTER INSTITUTE OF TECHNOLOGY   (United States)

Author keywords

HIV 1; LRRK2; Microglia; Neuroinflammation; Neurotoxicity; Parkinson s disease

Indexed keywords

BETA TUBULIN; CASPASE 3; CD11B ANTIGEN; CXCL2 CHEMOKINE; INTERLEUKIN 6; LEUCINE RICH REPEAT KINASE 2; MICROTUBULE ASSOCIATED PROTEIN 2; MONOCYTE CHEMOTACTIC PROTEIN 1; PHOSPHOTRANSFERASE INHIBITOR; PROTEIN P46; PROTEIN P54; STRESS ACTIVATED PROTEIN KINASE; SYNAPSIN I; SYNAPTOPHYSIN; TRANSACTIVATOR PROTEIN; TUJ 1 PROTEIN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VESICULAR GLUTAMATE TRANSPORTER; AUTACOID; BIOLOGICAL MARKER; LRRK2 PROTEIN, MOUSE; MITOGEN ACTIVATED PROTEIN KINASE P38; NEUROPROTECTIVE AGENT; PROTEIN SERINE THREONINE KINASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL CULTURE; CELL STRUCTURE; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME LINKED IMMUNOSORBENT ASSAY; HIV ASSOCIATED DEMENTIA; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IMAGE ANALYSIS; IMMUNOCYTOCHEMISTRY; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; MICROGLIA; MOUSE; NERVOUS SYSTEM INFLAMMATION; NEUROPROTECTION; NEUROTOXICITY; NEUTROPHIL CHEMOTAXIS; NONHUMAN; PARKINSON DISEASE; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; STEREOTACTIC PROCEDURE; WESTERN BLOTTING; ANIMAL; BRAIN CORTEX; CHEMICALLY INDUCED; COGNITIVE DEFECT; COMPLICATION; DRUG EFFECTS; GENE EXPRESSION; GENE EXPRESSION REGULATION; GENETICS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFLAMMATION; KNOCKOUT MOUSE; METABOLISM; MICROINJECTION; NERVE DEGENERATION; PHYSIOLOGY; PRIMARY CELL CULTURE;

AIDS DEMENTIA COMPLEX; ANIMALS; BIOMARKERS; CEREBRAL CORTEX; COGNITION DISORDERS; GENE EXPRESSION; GENE EXPRESSION REGULATION; GENE PRODUCTS, TAT; HIV INFECTIONS; INFLAMMATION; INFLAMMATION MEDIATORS; JNK MITOGEN-ACTIVATED PROTEIN KINASES; MICE; MICE, KNOCKOUT; MICROGLIA; MICROINJECTIONS; NERVE DEGENERATION; NEUROPROTECTIVE AGENTS; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PRIMARY CELL CULTURE; PROTEIN-SERINE-THREONINE KINASES;

EID: 84929334186     PISSN: 02706474     EISSN: 15292401     Source Type: Journal    
DOI: 10.1523/JNEUROSCI.0650-14.2015     Document Type: Article

References (54)

1. Allen C, Thornton P, Denes A, McColl BW, Pierozynski A, Monestier M, Pinteaux E, Rothwell NJ, Allan SM (2012) Neutrophil cerebrovascular transmigration triggers rapid neurotoxicity through release of proteases associated with decondensed DNA. J Immunol 189:381–392.
2. Anderson E, Zink W, Xiong H, Gendelman HE (2002) HIV-1-associated dementia: a metabolic encephalopathy perpetrated by virus-infected and immune-competent mononuclear phagocytes. J Acquir Immune Defic Syndr 31 [Suppl 2]:S43–S54.
3. Bocchini V, Mazzolla R, Barluzzi R, Blasi E, Sick P, Kettenmann H (1992) An immortalized cell line expresses properties of activated microglial cells. J Neurosci Res 31:616–621.
4. Brown GC, Neher JJ (2012) Eaten alive! Cell death by primary phagocytosis: “phagoptosis.” Trends Biochem Sci 37:325–332.
5. Burguillos MA, Deierborg T, Kavanagh E, Persson A, Hajji N, Garcia Quintanilla A, Cano J, Brundin P, Englund E, Venero JL, Joseph B (2011) Caspase signalling controls microglia activation and neurotoxicity. Nature 472:319–324.
6. Buscemi L, Ramonet D, Geiger JD (2007) Human immunodeficiency virus type-1 protein Tat induces tumor necrosis factor-alpha-mediated neurotoxicity. Neurobiol Dis 26:661–670.
7. Cross HM, Combrinck MI, Joska JA (2013) HIV-associated neurocognitive disorders: antiretroviral regimen, central nervous system penetration ef fectiveness, and cognitive outcomes. S Afr Med J 103:758–762.
8. Deng X, Dzamko N, Prescott A, Davies P, Liu Q, Yang Q, Lee JD, Patricelli MP, Nomanbhoy TK, Alessi DR, Gray NS (2011) Characterization of a selective inhibitor of the Parkinson’s disease kinase LRRK2. Nat Chem Biol 7:203–205.
9. Dzamko N, Deak M, Hentati F, Reith AD, Prescott AR, Alessi DR, Nichols RJ (2010) Inhibition of LRRK2 kinase activity leads to dephosphorylation of Ser(910)/Ser(935), disruption of 14-3-3 binding and altered cytoplasmic localization. Biochem J 430:405–413.
10. Ellis R, Langford D, Masliah E (2007) HIV and antiretroviral therapy in the brain: neuronal injury and repair. Nat Rev Neurosci 8:33–44.
11. Gandhi PN, Chen SG, Wilson-Delfosse AL (2009) Leucine-rich repeat kinase 2 (LRRK2): a key player in the pathogenesis of Parkinson’s disease. J Neurosci Res 87:1283–1295.
12. Gloeckner CJ, Schumacher A, Boldt K, Ueffing M (2009) The Parkinson disease-associated protein kinase LRRK2 exhibits MAPKKK activity and phosphorylates MKK3/6 and MKK4/7, in vitro. J Neurochem 109:959– 968.
13. Gloeckner CJ, Boldt K, von Zweydorf F, Helm S, Wiesent L, Sarioglu H, Ueffing M (2010) Phosphopeptide analysis reveals two discrete clusters of phosphorylation in the N-terminus and the Roc domain of the Parkinson-disease associated protein kinase LRRK2. J Proteome Res 9:1738–1745.
14. Glynn MW, McAllister AK (2006) Immunocytochemistry and quantification of protein colocalization in cultured neurons. Nat Protoc 1:1287– 1296.
15. Greggio E, Civiero L, Bisaglia M, Bubacco L (2012) Parkinson’s disease and immune system: is the culprit LRRKing in the periphery? J Neuroinflammation 9:94.
16. Heaton RK, Clifford DB, Franklin DR Jr, Woods SP, Ake C, Vaida F, Ellis RJ, Letendre SL, Marcotte TD, Atkinson JH, Rivera-Mindt M, Vigil OR, Taylor MJ, Collier AC, Marra CM, Gelman BB, McArthur JC, Morgello S, Simpson DM, McCutchan JA, et al. (2010) HIV-associated neurocognitive disorders persist in the era of potent antiretroviral therapy: CHARTER Study. Neurology 75:2087–2096.
17. Henn A, Lund S, Hedtjärn M, Schrattenholz A, Pörzgen P, Leist M (2009) The suitability of BV2 cells as alternative model system for primary microglia cultures or for animal experiments examining brain inflammation. ALTEX 26:83–94.
18. Hinkle KM, Yue M, Behrouz B, Dächsel JC, Lincoln SJ, Bowles EE, Beevers JE, Dugger B, Winner B, Prots I, Kent CB, Nishioka K, Lin WL, Dickson DW, Janus CJ, Farrer MJ, Melrose HL (2012) LRRK2 knockout mice have an intact dopaminergic system but display alterations in exploratory and motor co-ordination behaviors. Mol Neurodegener 7:25.
19. Hirsch S, Gordon S (1983) Polymorphic expression of a neutrophil differentiation antigen revealed by monoclonal antibody 7/4. Immunogenetics 18:229–239.
20. Hofman FM, Chen P, Incardona F, Zidovetzki R, Hinton DR (1999) HIV-1 tat protein induces the production of interleukin-8 by human brainderived endothelial cells. J Neuroimmunol 94:28–39.
21. Hopcroft L, Bester L, Clement D, Quigley A, Sachdeva M, Rourke SB, Nixon SA (2013) “My body’s a 50 year-old but my brain is definitely an 85 year-old”: exploring the experiences of men ageing with HIV-associated neurocognitive challenges. J Int AIDS Soc 16:18506.
22. Horvath RJ, Nutile-McMenemy N, Alkaitis MS, Deleo JA (2008) Differential migration, LPS-induced cytokine, chemokine, and NO expression in immortalized BV-2 and HAPI cell lines and primary microglial cultures. J Neurochem 107:557–569.
23. Jones M, Olafson K, Del Bigio MR, Peeling J, Nath A (1998) Intraventricular injection of human immunodeficiency virus type 1 (HIV-1) tat protein causes inflammation, gliosis, apoptosis, and ventricular enlargement. J Neuropathol Exp Neurol 57:563–570.
24. Kim B, Yang MS, Choi D, Kim JH, Kim HS, Seol W, Choi S, Jou I, Kim EY, Joe EH (2012) Impaired inflammatory responses in murine lrrk2-knockdown brain microglia. PLoS One 7:e34693.
25. Kure K, Lyman WD, Weidenheim KM, Dickson DW (1990) Cellular localization of an HIV-1 antigen in subacute AIDS encephalitis using an improved double-labeling immunohistochemical method. Am J Pathol 136: 1085–1092.
26. Li X, Wang QJ, Pan N, Lee S, Zhao Y, Chait BT, Yue Z(2011) Phosphorylation-dependent 14-3-3 binding to LRRK2 is impaired by common mutations of familial Parkinson’s disease. PLoS One 6:e17153.
27. Liu Z, Galemmo RA Jr, Fraser KB, Moehle MS, Sen S, Volpicelli-Daley LA, DeLucas LJ, Ross LJ, Valiyaveettil J, Moukha-Chafiq O, Pathak AK, Ananthan S, Kezar H, White EL, Gupta V, Maddry JA, Suto MJ, West AB(2014) Unique functional and structural properties of the LRRK2 protein ATP-binding pocket. J Biol Chem 289:32937–32951.
28. Lu SM, Tremblay MÈ, King IL, Qi J, Reynolds HM, Marker DF, Varrone JJ, Majewska AK, Dewhurst S, Gelbard HA (2011) HIV-1 Tat-induced microgliosis and synaptic damage via interactions between peripheral and central myeloid cells. PLoS One 6:e23915
29. Luerman GC, Nguyen C, Samaroo H, Loos P, Xi H, Hurtado-Lorenzo A, Needle E, Stephen Noell G, Galatsis P, Dunlop J, Geoghegan KF, Hirst WD (2014) Phosphoproteomic evaluation of pharmacological inhibition of leucine-rich repeat kinase 2 reveals significant off-target effects of LRRK-2-IN-1. J Neurochem 128:561–576.
30. MacLeod D, Dowman J, Hammond R, Leete T, Inoue K, Abeliovich A (2006) The familial Parkinsonism gene LRRK2 regulates neurite process morphology. Neuron 52:587–593.
31. Marker DF, Tremblay ME, Lu SM, Majewska AK, Gelbard HA(2010) A thin-skull window technique for chronic two-photon in vivo imaging of murine microglia in models of neuroinflammation. J Vis Exp pii:2059
32. Marker DF, Puccini JM, Mockus TE, Barbieri J, Lu SM, Gelbard HA(2012) LRRK2 kinase inhibition prevents pathological microglial phagocytosis in response to HIV-1 Tat protein. J Neuroinflammation 9:261.
33. Marker DF, Tremblay MÈ, Puccini JM, Barbieri J, Gantz Marker MA, Loweth CJ, Muly EC, Lu SM, Goodfellow VS, Dewhurst S, Gelbard HA(2013) The new small-molecule mixed-lineage kinase 3 inhibitor URMC-099 is neuroprotective and anti-inflammatory in models of human immunodeficiency virus-associated neurocognitive disorders. J Neurosci 33:9998– 10010.
34. Masliah E, Ge N, Mucke L (1996) Pathogenesis of HIV-1 associated neurodegeneration. Crit Rev Neurobiol 10:57–67.
35. McLean IW, Nakane PK (1974) Periodate-lysine-paraformaldehyde fixative. A new fixation for immunoelectron microscopy. J Histochem Cytochem 22:1077–1083.
36. Melrose H, Lincoln S, Tyndall G, Dickson D, Farrer M(2006) Anatomical localization of leucine-rich repeat kinase 2 in mouse brain. Neuroscience 139:791–794.
37. Moehle MS, Webber PJ, Tse T, Sukar N, Standaert DG, DeSilva TM, Cowell RM, West AB (2012) LRRK2 inhibition attenuates microglial inflammatory responses. J Neurosci 32:1602–1611.
38. Morales D, Skoulakis EC, Acevedo SF (2012) 14-3-3s are potential biomarkers for HIV-related neurodegeneration. J Neurovirol 18:341–353.
39. Nichols RJ, Dzamko N, Morrice NA, Campbell DG, Deak M, Ordureau A, Macartney T, Tong Y, Shen J, Prescott AR, Alessi DR (2010) 14-3-3 binding to LRRK2 is disrupted by multiple Parkinson’s disease-associated mutations and regulates cytoplasmic localization. Biochem J 430:393–404.
40. Nimmerjahn A, Kirchhoff F, Helmchen F (2005) Resting microglial cells are highly dynamic surveillants of brain parenchyma in vivo. Science 308: 1314–1318.
41. Reith AD, Bamborough P, Jandu K, Andreotti D, Mensah L, Dossang P, Choi HG, Deng X, Zhang J, Alessi DR, Gray NS (2012) GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. Bioorg Med Chem Lett 22:5625–5629.
42. Seol W (2010) Biochemical and molecular features of LRRK2 and its pathophysiological roles in Parkinson’s disease.BMB Rep 43:233–244.
43. Stansley B, Post J, Hensley K (2012) A comparative review of cell culture systems for the study of microglial biology in Alzheimer’s disease. J Neuroinflammation 9:115.
44. Sui Z, Fan S, Sniderhan L, Reisinger E, Litzburg A, Schifitto G, Gelbard HA, Dewhurst S, Maggirwar SB(2006) Inhibition of mixed lineage kinase 3 prevents HIV-1 Tat-mediated neurotoxicity and monocyte activation. J Immunol 177:702–711.
45. Tremblay MÈ, Stevens B, Sierra A, Wake H, Bessis A, Nimmerjahn A (2011) The role of microglia in the healthy brain. J Neurosci 31:16064–16069.
46. Tremblay MÈ, Marker DF, Puccini JM, Mully EC, Lu SM, Gelbard HA (2013) Ultrastructure of microglia-synapse interactions in the HIV-1 Tat-injected murine central nervous system. Commun Integr Biol 6:e27670.
47. Tyor WR, Glass JD, Griffin JW, Becker PS, McArthur JC, Bezman L, Griffin DE (1992) Cytokine expression in the brain during the acquired immunodeficiency syndrome. Ann Neurol 31:349–360.
48. West AB, Moore DJ, Choi C, Andrabi SA, Li X, Dikeman D, Biskup S, Zhang Z, Lim KL, Dawson VL, Dawson TM (2007) Parkinson’s diseaseassociated mutations in LRRK2 link enhanced GTP-binding and kinase activities to neuronal toxicity. Hum Mol Genet 16:223–232.
49. Winner B, Melrose HL, Zhao C, Hinkle KM, Yue M, Kent C, Braithwaite AT, Ogholikhan S, Aigner R, Winkler J, Farrer MJ, Gage FH (2011) Adult neurogenesis and neurite outgrowth are impaired in LRRK2 G2019S mice. Neurobiol Dis 41:706–716.
50. Wolf Y, Yona S, Kim KW, Jung S (2013) Microglia, seen from the CX3CR1 angle. Front Cell Neurosci 7:26.
51. Xing HQ, Hayakawa H, Izumo K, Kubota R, Gelpi E, Budka H, Izumo S (2009) In vivo expression of proinflammatory cytokines in HIV encephalitis: an analysis of 11 autopsy cases. Neuropathology 29:433–442.
52. Yuan L, Qiao L, Wei F, Yin J, Liu L, Ji Y, Smith D, Li N, Chen D (2013) Cytokines in CSF correlate with HIV-associated neurocognitive disorders in the post-HAART era in China. J Neurovirol 19:144–149.
53. Zheng JC, Huang Y, Tang K, Cui M, Niemann D, Lopez A, Morgello S, Chen S (2008) HIV-1-infected and/or immune-activated macrophages regulate astrocyte CXCL8 production through IL-1beta and TNF-alpha: involvement of mitogen-activated protein kinases and protein kinase R. J Neuroimmunol 200:100–110.
54. Zimprich A, Biskup S, Leitner P, Lichtner P, Farrer M, Lincoln S, Kachergus J, Hulihan M, Uitti RJ, Calne DB, Stoessl AJ, Pfeiffer RF, Patenge N, Carbajal IC, Vieregge P, Asmus F, Müller-Myhsok B, Dickson DW, Meitinger T, Strom TM, et al. (2004) Mutations in LRRK2 cause autosomaldominant parkinsonism with pleomorphic pathology. Neuron 44:601– 607.